Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2026-04-22 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
董事会关于独立董事独立性自查情况的专项报告
Governance Information Classification · 90% confidence The document is a special report issued by the board assessing the independence of the company’s independent directors, referencing regulatory rules on independent director governance. This is not a full annual or interim report, not an earnings release or voting result, but rather a governance compliance report. It therefore fits the Governance Information category (CGR).
2026-04-22 Chinese
2025年度会计师事务所履职情况评估报告
Regulatory Filings Classification · 75% confidence The document is a detailed evaluation report by the company’s audit committee on the performance and independence of its appointed external auditor for 2025. It is not an Annual Report or the audited financial statements themselves, nor is it an earnings release, dividend notice, M&A announcement, or management discussion. It is also not a simple notice announcing publication of another report. There is no specific slot in our taxonomy for an auditor performance evaluation, so this falls under the fallback category “Regulatory Filings (RNS).”
2026-04-22 Chinese
益丰药房关于2025年年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 85% confidence The document is a detailed专项报告 (“special report”) on the deposit, management, and actual use of funds raised via convertible bond issuance in 2024, covering account storage, investment, and utilization through 2025. It is clearly a post-financing report on fundraising proceeds, not an ESG report, annual report, or simple publication notice. The content focuses on the fundraising capital structure and actual application of proceeds, fitting best under Capital/Financing Update (CAP).
2026-04-22 Chinese
益丰药房2025年度募集资金存放、管理与实际使用情况鉴证报告
Audit Report / Information Classification · 89% confidence The document is a detailed CPA assurance (鉴证) report on the annual deposit, management, and actual use of funds raised (募集资金) by the company, prepared under regulatory listing rules. It is not an AGM presentation, earnings release, or just an announcement of publication, but a standalone audit/assurance report verifying compliance with the listed company fundraising rules. Therefore it fits the “Audit Report / Information” category (Code: AR). FY 2025
2026-04-22 Chinese
益丰药房2025年年度报告
Annual Report Classification · 100% confidence The document is titled "益丰大药房连锁股份有限公司2025 年年度报告" which translates to "Yifeng Pharmacy Chain Co., Ltd. 2025 Annual Report." It contains detailed financial data, management discussion and analysis, company information, financial indicators, and audit opinions. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes sections such as "管理层讨论与分析" (Management Discussion and Analysis), financial statements, and auditor's report, which are typical components of an Annual Report. The presence of audit opinions and detailed financial data confirms it is not just an audit report or a regulatory filing. Therefore, the document is classified as an Annual Report (10-K). FY 2025
2026-04-22 Chinese
益丰药房2025年度审计报告
Regulatory Filings
2026-04-22 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.